Vascular endothelial growth factor as a predictive marker for POEMS syndrome treatment response: Retrospective cohort study

S. Misawa, Yasunori Sato, K. Katayama, H. Hanaoka, S. Sawai, M. Beppu, F. Nomura, K. Shibuya, Y. Sekiguchi, Y. Iwai, K. Watanabe, H. Amino, C. Ohwada, M. Takeuchi, E. Sakaida, C. Nakaseko, S. Kuwabara

研究成果: Article

30 引用 (Scopus)

抜粋

Objective: POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes) syndrome is a rare multisystem disease characterised by plasma cell dyscrasia and overproduction of vascular endothelial growth factor (VEGF). VEGF is assumed to be useful in monitoring disease activity, because VEGF levels usually decrease after treatment. However, there is no study to investigate whether the extent of decrease in VEGF correlates with clinical outcome. We tested the predictive efficacy of serum VEGF levels in POEMS syndrome. Method: This was an institutional review board approved retrospective observational cohort study of 20 patients with POEMS monitored regularly for more than 12 months (median follow-up, 87 months) after treatment onset using our prospectively accumulated database of POEMS from 1999 to 2015. Patients were treated by autologous peripheral blood stem cell transplantation or thalidomide administration. Serum VEGF was measured by ELISA. Outcome measures included clinical and laboratory findings and relapsefree survival. Results: Serum VEGF levels decreased rapidly after treatment, and stabilised by 6 months post treatment. Patients with normalised serum VEGF levels (<1040 pg/mL) at 6 months showed prolonged relapsefree survival (HR=12.81, 95% CI 2.691 to 90.96; p=0.0001) and greater later clinical improvement. The rate of serum VEGF reduction over the first 6 months post treatment correlated with increased grip strength, serum albumin levels, and compound muscle action potential amplitudes at 12 months. Conclusions: Serum VEGF level at 6 months post treatment is a predicative biomarker for disease activity and prognosis in POEMS syndrome. Serum VEGF could be used as a surrogate endpoint for relapse-free survival or clinical or laboratory improvement of POEMS syndrome for clinical trials.

元の言語English
記事番号e009157
ジャーナルBMJ open
5
発行部数11
DOI
出版物ステータスPublished - 2015 1 1
外部発表Yes

    フィンガープリント

ASJC Scopus subject areas

  • Medicine(all)

これを引用

Misawa, S., Sato, Y., Katayama, K., Hanaoka, H., Sawai, S., Beppu, M., Nomura, F., Shibuya, K., Sekiguchi, Y., Iwai, Y., Watanabe, K., Amino, H., Ohwada, C., Takeuchi, M., Sakaida, E., Nakaseko, C., & Kuwabara, S. (2015). Vascular endothelial growth factor as a predictive marker for POEMS syndrome treatment response: Retrospective cohort study. BMJ open, 5(11), [e009157]. https://doi.org/10.1136/bmjopen-2015-009157